Public perception of psychedelic researchers’ integrity is influenced by their personal substance use and cultural associations, impacting the credibility and reception of their work

The safety and efficacy of microdosing psychedelic drugs like LSD and psilocybin are still uncertain due to contradictory results and study limitations, highlighting the need for further robust research.

Despite a resurgence in research on psychedelics over the last two decades, we still have little insight into the psychedelics user population, making difficult for researchers to contextualise and assess the broader validity of their findings.

Most users do not test their substances before microdosing, highlighting the need for increased safety measures and further research to validate these benefits.

Magic mushroom users generally perceive these psychedelics as less harmful than many other substances, highlighting the importance of addressing the discrepancy between actual harm, societal perceptions, and legal classifications to inform safer use practices and policies.

Long-term changes in psychological functioning, including personality, attitudes, depression, spirituality, and wellbeing, can occur after the use of psychedelics like psilocybin, with reduced adverse side effects when proper screening, preparation, supervision, and integration are in place.

Long-term changes in psychological functioning, including personality, attitudes, depression, spirituality, and wellbeing, can occur after the use of psychedelics like psilocybin, with limited adverse side effects when proper screening, preparation, supervision, and integration are in place.

Bad trips and long-term negative outcomes from psilocybin use are more likely in female users, those who take multiple doses in one session, or combine it with other substances, while single high doses can lead to medical emergencies.

Historical evidence from Modum Bad's psychedelic therapy program highlights the importance of acknowledging and preparing for potential long-term harms in contemporary psychedelic treatments.

The majority of users reported favorable experiences with 2C-B, likening its effects to MDMA and LSD, while NBOMe was generally viewed unfavorably and DOx was criticized for its prolonged effects; understanding these subjective experiences can enhance harm reduction efforts in psychedelic use.